Undifferentiated Connective Tissue Disease

Undifferentiated connective tissue disease (UCTD) is a systemic autoimmune condition with features and autoantibodies suggesting a connective tissue disease, but not meeting classification criteria for a defined disease.

• Predominantly women aged 30 to 50; ANA positive, often with anti-Ro/SSA, anti-RNP.

• About 20 to 30% evolve into a defined disease within 5 years (lupus, Sjögren, systemic sclerosis, rheumatoid arthritis, myositis); the majority stay stable or remit.

• Predictors of evolution: Raynaud, autoantibody specificities, pulmonary involvement, ILD.

• Pregnancy is associated with risks (anti-Ro/La: neonatal lupus, heart block).

• Raynaud phenomenon, arthralgia or non-erosive arthritis, sicca symptoms, photosensitive rash, oral ulcers, serositis, fatigue, low grade fever.

• Mild cytopenias, hair loss, mild muscle symptoms.

• Visceral involvement is uncommon.

• ANA (immunofluorescence), ENA panel (anti-Ro, La, Sm, RNP, Scl-70, centromere, Jo-1), anti-dsDNA, rheumatoid factor, anti-CCP, complement C3/C4, antiphospholipid antibodies.

• Count, ESR/CRP, creatinine, urinalysis, CK, liver tests, thyroid.

• Nailfold capillaroscopy, chest radiograph, PFTs and echocardiography if respiratory or Raynaud symptoms.

• Exclude infection, malignancy, drug-induced autoimmunity, fibromyalgia, thyroid disease, other defined rheumatic disease.

• Review every 3 to 6 months for emerging criteria.

• Reassurance, education, sun protection, smoking cessation, vaccination.

• Symptomatic: NSAIDs (naproxen 500 mg twice daily) for arthralgia, hydroxychloroquine 200 to 400 mg daily (up to 5 mg/kg) for arthralgia, rash, fatigue and to reduce flares (annual retinal screening after 5 years).

• Short low dose prednisolone 5 to 10 mg for flares; methotrexate 10 to 20 mg weekly for persistent arthritis.

• Raynaud: avoid cold, nifedipine 30 mg daily.

• Antiphospholipid antibodies: low dose aspirin 75 to 100 mg if high risk.

• Pregnancy planning: disease inactive for 6 months; hydroxychloroquine continued; aspirin 75 to 150 mg from 12 weeks; fetal heart monitoring in anti-Ro positive women (weeks 16 to 26).

• Follow up every 3 to 6 months initially, then yearly if stable.